Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicky M Avery

Showing results (171-180 of 220) with videos related to

Pageof 22
Sort By:
Nature Communications|April 7, 2017
Erratum: SC83288 is a clinical development candidate for the treatment of severe malariaStefano Pegoraro, Maëlle Duffey, Thomas D Otto, et al.
European Journal of Medicinal Chemistry|February 20, 2021
Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasionWilliam Nguyen, Madeline G Dans, Anna Ngo, et al.
RSC Medicinal Chemistry|February 19, 2025
Heterocyclic core modifications in trypanosomacidal 2-[(phenylheteroaryl)ethyl]ureasArthur Toynton, Lori Ferrins, Harriet L Newson, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent <i>N</i>-Ethylurea Pyrazole Derivatives as Dual Inhibitors of <i>Trypanosoma brucei</i> and <i>Trypanosoma cruzi</i>Swapna Varghese, Raphaël Rahmani, Stephanie Russell, et al.
European Journal of Medicinal Chemistry|June 7, 2014
Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stagesFinn K Hansen, Subathdrage D M Sumanadasa, Katharina Stenzel, et al.
European Journal of Medicinal Chemistry|July 9, 2013
3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasisLori Ferrins, Raphaël Rahmani, Melissa L Sykes, et al.
The Journal of Clinical Investigation|February 12, 2020
A Plasmodium vivax experimental human infection model for evaluating efficacy of interventionsKatharine A Collins, Claire Yt Wang, Matthew Adams, et al.
Malaria Journal|April 16, 2014
Repositioning: the fast track to new anti-malarial medicines?Julie Lotharius, Francisco Javier Gamo-Benito, Iñigo Angulo-Barturen, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2015
Splenic retention of Plasmodium falciparum gametocytes to block the transmission of malariaJulien Duez, John P Holleran, Papa Alioune Ndour, et al.
Journal of Medicinal Chemistry|June 28, 2017
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered PerorallyMichael Leven, Tanja C Knaab, Jana Held, et al.
Pageof 22

Showing results (171-180 of 220) with videos related to

Sort By:
Pageof 22
Nature Communications|April 7, 2017
Erratum: SC83288 is a clinical development candidate for the treatment of severe malariaStefano Pegoraro, Maëlle Duffey, Thomas D Otto, et al.
European Journal of Medicinal Chemistry|February 20, 2021
Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasionWilliam Nguyen, Madeline G Dans, Anna Ngo, et al.
RSC Medicinal Chemistry|February 19, 2025
Heterocyclic core modifications in trypanosomacidal 2-[(phenylheteroaryl)ethyl]ureasArthur Toynton, Lori Ferrins, Harriet L Newson, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent <i>N</i>-Ethylurea Pyrazole Derivatives as Dual Inhibitors of <i>Trypanosoma brucei</i> and <i>Trypanosoma cruzi</i>Swapna Varghese, Raphaël Rahmani, Stephanie Russell, et al.
European Journal of Medicinal Chemistry|June 7, 2014
Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stagesFinn K Hansen, Subathdrage D M Sumanadasa, Katharina Stenzel, et al.
European Journal of Medicinal Chemistry|July 9, 2013
3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasisLori Ferrins, Raphaël Rahmani, Melissa L Sykes, et al.
The Journal of Clinical Investigation|February 12, 2020
A Plasmodium vivax experimental human infection model for evaluating efficacy of interventionsKatharine A Collins, Claire Yt Wang, Matthew Adams, et al.
Malaria Journal|April 16, 2014
Repositioning: the fast track to new anti-malarial medicines?Julie Lotharius, Francisco Javier Gamo-Benito, Iñigo Angulo-Barturen, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2015
Splenic retention of Plasmodium falciparum gametocytes to block the transmission of malariaJulien Duez, John P Holleran, Papa Alioune Ndour, et al.
Journal of Medicinal Chemistry|June 28, 2017
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered PerorallyMichael Leven, Tanja C Knaab, Jana Held, et al.
Pageof 22